Soleno Therapeutics (SLNO)
(Delayed Data from NSDQ)
$46.57 USD
-0.46 (-0.97%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $46.60 +0.04 (0.08%) 4:18 PM ET
3-Hold of 5 3
C Value C Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$46.57 USD
-0.46 (-0.97%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $46.60 +0.04 (0.08%) 4:18 PM ET
3-Hold of 5 3
C Value C Growth A Momentum C VGM
Zacks News
Soleno Stock Up as FDA Accepts PWS Drug NDA Under Priority Review
by Zacks Equity Research
SLNO stock gains 6.3% as FDA accepts regulatory filing for lead candidate, DCCR, to treat hyperphagia associated with PWS under Priority Review.
Soleno Therapeutics, Inc. (SLNO) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Soleno Therapeutics, Inc. (SLNO) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Here's Why Momentum in Soleno Therapeutics, Inc. (SLNO) Should Keep going
by Zacks Equity Research
Soleno Therapeutics, Inc. (SLNO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Here's What Could Help Soleno Therapeutics, Inc. (SLNO) Maintain Its Recent Price Strength
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Soleno Therapeutics, Inc. (SLNO) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Biotech Stock Roundup: ICPT Up on Buyout Deal, IMVT & PLRX Gain on Study Data
by Zacks Equity Research
Acquisition news from Intercept (ICPT) and study updates from Immunovant (IMVT) are in focus in the biotech sector.
Soleno (SLNO) Soars as Prader-Willi Syndrome Study Meets Goal
by Zacks Equity Research
Soleno's (SLNO) shares rally as the late-stage study evaluating diazoxide choline for patients with Prader-Willi syndrome meets its primary and secondary endpoints.
Soleno Therapeutics, Inc. (SLNO) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Soleno Therapeutics, Inc. (SLNO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Catalyst Pharmaceuticals (CPRX) Rallies 80.69% YTD: Here's Why
by Zacks Equity Research
Catalyst (CPRX) price rallies on FDA approval of the sNDA of its lead drug, Firdapse, approved to treat LEMS in patients above six years of age.
Catalyst Pharma's (CPRX) sNDA for Firdapse Approved by the FDA
by Zacks Equity Research
Catalyst Pharmaceuticals (CPRX) announces FDA approval of its sNDA for Firdapse to include pediatric patients for treating Lambert-Eaton myasthenic syndrome.
KemPharm (KMPH) Up On Positive Data From Sleep Disorder Study
by Zacks Equity Research
KemPharm (KMPH) reports positive top line from a study evaluating serdexmethylphenidate (SDX) for cardiovascular safety to progress the development of its prodrug KP1077.
Feneca (FENC) Gets FDA Nod for Cancer-Related Hearing Loss Drug
by Zacks Equity Research
Feneca Pharmaceuticals (FENC) receives FDA approval for Pedmark to reduce the risk of ototoxicity associated with cisplatin in pediatric patients with localized, non-metastatic solid tumors.
Aurinia's (AUPH) Oral Lupus Drug Lupkynis Gets European Approval
by Zacks Equity Research
Aurinia Pharmaceutical (AUPH) receives marketing authorization from the European Union for its orally administered CNI immunosuppressant, Lupkynis, for treating lupus nephritis.
Spectrum Pharmaceuticals (SPPI) Gets Nod for Rolvedon Injection
by Zacks Equity Research
Spectrum Pharmaceuticals (SPPI) receives FDA approval for its drug candidate, Rolvedon (eflapergrastim), for treating chemotherapy-induced neutropenia.
Viracta (VIRX) Up on Orphan Drug Tag for Peripheral Lymphoma
by Zacks Equity Research
Viracta (VIRX) receives Orphan Drug designation from the European Commission for its lead candidate Nana-val for treating peripheral T-cell lymphoma. Stock up.
Ironwood's (IRWD) Functional Constipation Study in Kids Succeeds
by Zacks Equity Research
Ironwood (IRWD) reports positive top-line data from a late-stage study evaluating Linzess (linaclotide) for functional constipation in pediatric patients aged six to 17 years.
RedHill (RDHL) Up on Orphan Drug Tag for NTM Disease Drug
by Zacks Equity Research
RedHill's (RDHL) RHB-204 gets Orphan Drug designation from the European Commission for the treatment of nontuberculous mycobacteria (NTM) disease
Here's Why Viracta Therapeutics (VIRX) is Up So Far This Year
by Zacks Equity Research
Viracta Therapeutics' (VIRX) Nana-val is being evaluated in multiple clinical studies in various subtypes of EBV-associated cancers.
Here's Why Assertio Holdings (ASRT) Stock is Up This Year
by Zacks Equity Research
Assertio Holdings' (ASRT) successful execution of its restructuring plan, resulting in significant cost savings, is boosting profits.
Zacks Industry Outlook Highlights Chinook Therapeutics, Assertio Holdings, Viracta Therapeutics and Soleno Therapeutics
by Zacks Equity Research
Chinook Therapeutics, Assertio Holdings, Viracta Therapeutics and Soleno Therapeutics are part of Zacks Industry Outlook article.
4 Small Stocks to Bet on in an Upbeat Drugs Industry
by Kinjel Shah
It is expected that innovation will continue to drive growth in the Medical-Drugs industry in 2022. KDNY, ASRT, VIRX, SLNO may prove to be good additions to one's portfolio.
KemPharm (KMPH) Stock Up on Deal to Acquire Orphazyme for $12.8M
by Zacks Equity Research
KemPharm (KMPH) inks deal to acquire Orphazyme A/S, which will add to its portfolio the latter's pipeline candidate, arimoclomol, being developed for treating Niemann-Pick disease type C. Shares rise.
Regulus (RGLS) Up as FDA Accepts IND for Kidney Disease Drug
by Zacks Equity Research
The FDA accepts Regulus' (RGLS) IND application for RGLS8429 to treat autosomal dominant polycystic kidney disease. The company plans to begin a phase I study in second-quarter 2022. Stock up.
Catalyst Pharmaceuticals (CPRX) Q1 Earnings Miss, Revenues Up Y/Y
by Zacks Equity Research
Catalyst's (CPRX) first-quarter 2022 earnings miss estimates while revenues meet the same.
Corcept's (CORT) Q1 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Corcept's (CORT) earnings as well as revenues miss estimates in the first quarter of 2022.
Pacira's (PCRX) Q1 Earnings Miss Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Pacira's (PCRX) earnings fall shy of estimates in the first quarter of 2022 while revenues beat the same.